You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

354 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
May 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Curative
Funding:
New Drug Funding Program
    Pegaspargase - Extranodal Natural Killer/T-cell Lymphoma
ODB - General Benefit
    dexamethasone
Jan 2022
Document
Document
Document
Document
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Curative
Funding:
New Drug Funding Program
    Durvalumab - Locally Advanced Unresectable Stage III Non-Small Cell Lung Cancer Following Concurrent Chemoradiation
Jun 2024
Regimen
Intent: Palliative
Funding:
Exceptional Access Program
    ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria
ODB - General Benefit
    letrozole
Sep 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Aug 2024

Pages